𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate

✍ Scribed by S. R. Patel; L. K. Kvols; R. G. Hahn; H. Windschitl; R. Levitt; T. Therneau

Publisher
John Wiley and Sons
Year
1990
Tongue
English
Weight
329 KB
Volume
66
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The dynamics of prostate specific antige
The dynamics of prostate specific antigen in hormone refractory prostate carcinoma : An analysis of Cancer and Leukemia Group B Study 9181 of megestrol acetate
✍ Robin T. Vollmer; Nancy A. Dawson; Nicholas J. Vogelzang πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 113 KB πŸ‘ 2 views

## BACKGROUND. Although many physicians measure serum prostate specific antigen (PSA) during the follow-up of patients with hormone refractory prostate carcinoma (HRPC), little has been done to formalize the determination of how these serial values of PSA impact on prognosis. To understand HRPC fu

Phase II study of the oral cyclophospham
Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients
✍ Catherine Maulard-Durdux; Bertrand Dufour; Christophe Hennequin; Y. ChrΓ©tien; Sy πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 413 KB πŸ‘ 1 views

## BACKGROUND. Hormonotherapy temporarily controls symptoms in 80% of patients with metastatic prostate carcinoma. Once progression occurs, no consensus exists on further therapy. Oral etoposide (vp-16) has shown clinical efficacy in advanced small cell lung carcinoma, breast cancer, germ cell tum

An eastern cooperative oncology group ph
An eastern cooperative oncology group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma
✍ Robert S. Witte; Paul Elson; Janardan Khandakar; Donald L. Trump πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 359 KB πŸ‘ 1 views

## Background. Trimetrexate is an antifol that differs from methotrexate in ways that may be clinically important. Because methotrexate has activity in advanced bladder cancer, this trial was initiated.